These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 8128201)

  • 1. [Systemic sclerosis (scleroderma): etiology and pathogenesis--where are we today?].
    Stoll T; Brühlmann P; Fontana A; Gmür J; Michel BA
    Schweiz Med Wochenschr; 1994 Feb; 124(5):193-203. PubMed ID: 8128201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of dermal connective tissue in scleroderma.
    Kähäri VM
    Ann Med; 1993 Dec; 25(6):511-8. PubMed ID: 8292298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunopathological disturbances in systemic sclerosis].
    Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
    Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic sclerosis--clinical course and treatment possibilities].
    Szymańska E; Maj M; Rudnicka L
    Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
    Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
    Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 1: pathogenesis].
    Zuber JP; Chizzolini C; Leimgruber A; Bart PA; Spertini F
    Rev Med Suisse; 2006 Apr; 2(62):1052-7. PubMed ID: 16711150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.
    Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV
    Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Physiopathology of scleroderma].
    Fleischmajer R; Perlish JS; Maquart FX; Kalis B
    Ann Dermatol Venereol; 1993; 120(2):157-66. PubMed ID: 8363310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of scleroderma: an update.
    Haustein UF; Anderegg U
    J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):1-8. PubMed ID: 9731958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic susceptibility to systemic sclerosis from clinical aspect to genetic factor analyses.
    Granel B; Bernard F; Chevillard C
    Eur J Intern Med; 2009 May; 20(3):242-52. PubMed ID: 19393491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunopathogenesis of scleroderma--evolving concepts.
    Sapadin AN; Esser AC; Fleischmajer R
    Mt Sinai J Med; 2001; 68(4-5):233-42. PubMed ID: 11514910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vascular manifestations in systemic sclerosis (scleroderma)].
    Cafagna D; Melon F; Balbi M; Ponte E
    Minerva Med; 1998 May; 89(5):153-61. PubMed ID: 9676180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic autoantibodies in systemic sclerosis.
    Gabrielli A; Svegliati S; Moroncini G; Avvedimento EV
    Curr Opin Immunol; 2007 Dec; 19(6):640-5. PubMed ID: 18083509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunobiology of systemic sclerosis.
    Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
    Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal model of systemic sclerosis.
    Yamamoto T
    J Dermatol; 2010 Jan; 37(1):26-41. PubMed ID: 20175838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic sclerosis: symptomatic treatment].
    Dziankowska-Bartkowiak B; Waszczykowska E; Skretkowicz K
    Pol Merkur Lekarski; 2003 Sep; 15(87):259-62. PubMed ID: 14679853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and environmental factors in systemic sclerosis.
    Fox RI; Kang HI
    Curr Opin Rheumatol; 1992 Dec; 4(6):857-61. PubMed ID: 1457281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of pathogenesis of systemic sclerosis.
    Abraham DJ; Krieg T; Distler J; Distler O
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii3-7. PubMed ID: 19487220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective.
    Yamamoto T; Nishioka K
    Exp Dermatol; 2005 Feb; 14(2):81-95. PubMed ID: 15679577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.